Abstract
Amyloid beta (Abeta) has been considered as a primary cause of Alzheimers disease (AD), and Abeta lowering approaches have been tested. Active immunization against Abeta is one of several promising Abeta-lowering approaches. Two mechanisms have been proposed: enhancement of microglial phagocytosis and Abeta sequestration (also called “peripheral sink”). We hypothesized that Abeta sequestration without immune modulation is sufficient to reduce the brain Abeta load and have demonstrated effective sequestration with Abeta binding agents that do not stimulate an immune reaction. Recent reports from other groups showed two other non-immune related Abeta binding agents, which have no structural relation to compounds we previously tested, reduced brain Abeta after peripheral administration. Congo red is a chemically synthesized small molecule that has binding affinity to Abeta. In the present study, we tested three Congo red derivatives in Abeta plaque-forming mice at an early pathological stage. Unfortunately, peripheral administration for three weeks did not substantially alter brain Abeta load. Optimized Abeta binding agents with high affinity to soluble Abeta are necessary for the sequestration approach.
Keywords: alzheimers disease (ad), immunization, transgenic mice, enoxaparin, brain, dmso, polyethylene glycol
Current Alzheimer Research
Title: An Aβ Sequestration Approach Using Non-Antibody Aβ Binding Agents
Volume: 2 Issue: 2
Author(s): Yasuji Matsuoka, Li Shao, Manik Debnath, John LaFrancois, Amanda Becker, Audrey Gray, Paul Aisen, Chester Mathis, William Klunk and Karen Duff
Affiliation:
Keywords: alzheimers disease (ad), immunization, transgenic mice, enoxaparin, brain, dmso, polyethylene glycol
Abstract: Amyloid beta (Abeta) has been considered as a primary cause of Alzheimers disease (AD), and Abeta lowering approaches have been tested. Active immunization against Abeta is one of several promising Abeta-lowering approaches. Two mechanisms have been proposed: enhancement of microglial phagocytosis and Abeta sequestration (also called “peripheral sink”). We hypothesized that Abeta sequestration without immune modulation is sufficient to reduce the brain Abeta load and have demonstrated effective sequestration with Abeta binding agents that do not stimulate an immune reaction. Recent reports from other groups showed two other non-immune related Abeta binding agents, which have no structural relation to compounds we previously tested, reduced brain Abeta after peripheral administration. Congo red is a chemically synthesized small molecule that has binding affinity to Abeta. In the present study, we tested three Congo red derivatives in Abeta plaque-forming mice at an early pathological stage. Unfortunately, peripheral administration for three weeks did not substantially alter brain Abeta load. Optimized Abeta binding agents with high affinity to soluble Abeta are necessary for the sequestration approach.
Export Options
About this article
Cite this article as:
Matsuoka Yasuji, Shao Li, Debnath Manik, LaFrancois John, Becker Amanda, Gray Audrey, Aisen Paul, Mathis Chester, Klunk William and Duff Karen, An Aβ Sequestration Approach Using Non-Antibody Aβ Binding Agents, Current Alzheimer Research 2005; 2 (2) . https://dx.doi.org/10.2174/1567205053585774
DOI https://dx.doi.org/10.2174/1567205053585774 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [ Hot Topic:Stroke Bugs: Current and Emerging Concepts Relevant to Infection in Cerebrovascular Disease (Guest Editors: Hedley CA Emsley and Angel Chamorro)]
Infectious Disorders - Drug Targets α-Lipoic Acid Supplementation: A Tool for Obesity Therapy?
Current Pharmaceutical Design Analysis of Univariate and Multivariate Filters Towards the Early Detection of Dementia
Recent Advances in Computer Science and Communications Pre-attentive Visual Processing in Alzheimer’s Disease: An Event-related Potential Study
Current Alzheimer Research High Content, Multi-Parameter Analyses in Buccal Cells to Identify Alzheimer’s Disease
Current Alzheimer Research Computer based Classification of MR Scans in First Time Applicant Alzheimer Patients
Current Alzheimer Research Strategies to Diminish the Ab Load in Alzheimers Disease
Current Medicinal Chemistry - Central Nervous System Agents Drugs for Targeted Therapies of Alzheimer’s Disease
Current Medicinal Chemistry The Multifactorial Nature of Alzheimer's Disease for Developing Potential Therapeutics
Current Topics in Medicinal Chemistry Chinese Medicinal Herbs as Source of Antioxidant Compounds – Where Tradition Meets the Future
Current Medicinal Chemistry Application of Sulfamic Acid in Organic Synthesis-A Short Review
Current Organic Chemistry Rheumatoid Arthritis: Genetic Variants as Biomarkers of Cardiovascular Disease
Current Pharmaceutical Design Pharmacological Strategies Against Glucocorticoid-mediated Brain Damage During Chronic Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Lipoic Acid, a Lead Structure for Multi-Target-Directed Drugs for Neurodegeneration
Mini-Reviews in Medicinal Chemistry Atrial Remodeling and Novel Pharmacological Strategies for Antiarrhythmic Therapy in Atrial Fibrillation
Current Medicinal Chemistry Dichotomous Life of DNA Binding High Mobility Group Box1 Protein in Human Health and Disease
Current Protein & Peptide Science Amyloid-β as a “Difficult Sequence” in Solid Phase Peptide Synthesis
Protein & Peptide Letters Brain Senescence and Neuroprotective Dietary Components
Central Nervous System Agents in Medicinal Chemistry Treating Cancer and No-Cancer Pain in Older and Oldest Old Patients
Current Pharmaceutical Design Miniaturization and Validation of the Ellmans Reaction Based Acetylcholinesterase Inhibitory Assay into 384-Well Plate Format and Screening of a Chemical Library
Combinatorial Chemistry & High Throughput Screening